Fu Yang

Fu Yang

Auto-generated profile, based on publicly available information

Fu Yang

Department of Pharmacology and Cancer Biology, Duke University School of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in Nature
Verified
Journal Article
Closed access
PDF file
FYFu Yang
Fu Yang
WSWeijia Su
Weijia Su
OCOliver W. Chung
Oliver W. Chung
LTLauren Tracy
Lauren Tracy
LWLu Wang
Lu Wang
ZZZz Zhao Zhang
Zz Zhao Zhang

11 March 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
OCOliver W. Chung
Oliver W. Chung
SYShun Yao
Shun Yao
LWLing Wang
Ling Wang
FYFu Yang
Fu Yang
LSLauren Schier
Lauren Schier
ZZZz Zhao Zhang
Zz Zhao Zhang
Extrachromosomal circular DNA (ecDNA) is frequently generated within the nucleus, contributing to genome dynamics and heterogeneity, thereby promoting cancer cell evolution and adaptation. However, the mechanisms underlying ecDNA biogenesis remain poorly understood. Here, using genome-wide CRISPR screening in human cells, we identified the BRCA1-A and the LIG4 complexes as key drivers of ecDNA production. Following DNA segmentation, the upstream BRCA1-A complex protects DNA ends from excessive resection, promoting end-joining for circularization. Conversely, the MRN complex, which mediates end resection and thus antagonizes the BRCA1-A complex, suppresses ecDNA formation. Downstream, LIG4 conservatively mediates ecDNA production by joining the free ends of the DNA fragments. Furthermore, ecDNA from patient tumors harbors junction sites with a LIG4 signature. Notably, disruption of either LIG4 or the BRCA1-A complex in cancer cells impairs ecDNA-mediated adaptation, hindering the development of resistance to both chemotherapy and targeted therapies. Together, our study reveals the roles of the LIG4 and BRCA1-A complexes in ecDNA biogenesis, and uncovers therapeutic targets to block ecDNA-mediated adaptation for cancer treatment.